SynthesisFrontiers in oncology2025
Hyperthermic intraperitoneal chemotherapy in ovarian cancer: a comprehensive review.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly recognized as a valuable adjunct to cytoreductive surgery (CRS) in the management of ovarian cancer with peritoneal dissemination. This comprehensive review synthesizes contemporary evidence on the efficacy, safety, and future directions of HIPEC across various clinical settings, including primary, interval, and recurrent disease. Landmark studies such as the OVHIPEC-1 trial have demonstrated significant survival benefits when HIPEC is integrated into interval cytoreductive surgery following neoadjuvant chemotherapy, with improvements in both progression-free and overall survival without increasing severe morbidity. Survival gains have also been observed in upfront settings, particularly in patients with stage III epithelial ovarian cancer. However, evidence in recurrent disease remains mixed, with some trials showing benefit and others showing no significant advantage. Critical to the success of HIPEC are optimal patient selection and surgical quality, with completeness of cytoreduction (CC0/CC1), low peritoneal cancer index (PCI), and biological factors such as tumor microenvironment composition emerging as key prognostic indicators. Although HIPEC is associated with a higher incidence of grade 3-5 adverse events, particularly renal and gastrointestinal toxicities, these are generally manageable in experienced centers. Enhanced recovery protocols and careful perioperative management have further improved safety profiles. Emerging innovations include combination with normothermic intraperitoneal chemotherapy, integration of immunotherapy such as intraperitoneal nivolumab, use of paclitaxel-based regimens, and exploration of minimally invasive techniques. Future directions also involve molecular profiling, AI-driven patient selection, and synergy with targeted therapies like PARP inhibitors. Ongoing research is essential to refine protocols, standardize patient selection, and integrate HIPEC into evolving systemic treatment landscapes. In conclusion, HIPEC represents a major advancement in the multimodal treatment of advanced ovarian cancer, offering meaningful survival benefits when applied in selected patients by multidisciplinary teams.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.